[1] ADAMS L A, ANSTEE Q M, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J]. Gut, 2017, 66(6):1138-1153. [2] ALEXANDER K S, ZAKAI N L, LIDOFSKY S D, et al. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk:The reasons for geographic and racial differences in stroke cohort[J]. PLoS One, 2018, 13(3):e0194153. [3] KIM D, TOUROS A, KIM W R. Nonalcoholic fatty liver disease and metabolic syndrome[J]. Clin Liver Dis,2018, 22(1):133-140. [4] BALLESTRI S, NASCIMBENI F, ROMAGNOLI D, et al. Type 2 diabetes in non-alcoholic fatty liver disease and hepatitis C virus infection-liver:The "Musketeer" in the spotlight[J]. Int J Mol Sci, 2016,17(3):355. [5] SUNNY N E, BRIL F, CUSI K. Mitochondrial adaptation in nonalcoholic fatty liver disease:novel mechanisms and treatment strategies[J]. Trends Endocrinol Metab, 2017, 28(4):250-260. [6] HONDA Y, IMAJO K, KATO T, et al. The selective SGLT2 inhibitor Ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice[J]. PLoS One, 2016, 11(1):e0146337. [7] ROMEO S, KOZLITINA J, XING C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease[J]. Nat Genet, 2008, 40(12):1461-1465. [8] KOLIAKI C, SZENDROEDI J, KAUL K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis[J]. Cell Metab, 2015, 21(5):739-746. [9] BOLINDER J, LJUNGGREN Ö, JOHANSSON L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Diabetes Obes Metab, 2014, 16(2):159-169. [10] SUISSA S. Lower risk of death with SGLT2 inhibitors in observational studies:real or bias?[J]. Diabetes Care, 2018,41(1):6-10. [11] YOUNOSSI Z M, KOENIG A B, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1):73-84. [12] LOMBARDI R, ONALI S, THORBURN D, et al. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD):An attempted network meta-analysis[J]. Cochrane Database Syst Rev, 2017, 3:CD011640. [13] KWOK R, CHOI K C, WONG G L, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements:A prospective cohort study[J]. Gut, 2016, 65(8):1359-1368. [14] ADAMS L A, HARMSEN S, STSAUVER J L, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes:A community-based cohort study[J]. Am J Gastroenterol,2010, 105(7):1567-1573. [15] EL-SERAG H B, HAMPEL H, JAVADI F. The association between diabetes and hepatocellular carcinoma:A systematic review of epidemiologic evidence[J]. Clin Gastroenterol Hepatol, 2006, 4(3):369-380. [16] NEUSCHWANDER-TETRI B A, LOOMBA R, SANYAL A J, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385(9972):956-965. [17] MOTA M, BANINI B A, CAZANAVE S C, et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease[J]. Metab Clin Exp, 2016, 65(8):1049-1061. [18] WANG D, LUO Y H, WANG X X, et al. The sodium-glucose cotransporter 2 inhibitor Dapagliflozin prevents renal and liver disease in western diet induced obesity mice[J]. Int J Mol Sci, 2018, 19(1):E137. [19] 舒筠然,李俊琪,刘琼.非酒精性脂肪性肝病的流行病学和危险因素分析[J]. 临床肝胆病杂志,2019, 35(9):2085-2090. |